CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
Valacyclovir +1 moredrug
Likely dose
Valacyclovir 1 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00514449
NCT00514449Phase 2Completed
CompareCT.gov

A Randomized Double-blind Controlled Trial of Valacyclovir Add-on Treatment of HSV Positive Early Course Schizophrenia Patients

Konasale Prasad·interventional·Posted Aug 10, 2007·Updated Jun 14, 2018

In Brief

A Phase 2 clinical trial evaluating Valacyclovir and Placebo for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 31 participants across 2 sites.

Detailed Summary

The purpose of this study is to examine whether antiviral medication will help improve psychotic symptoms and cognition in individuals early in the course of schizophrenia or schizoaffective disorder who are exposed to herpes simplex virus, type 1 (HSV 1), a virus that causes commonly occurring and recurrent cold sores.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
CollaboratorsStanley Medical Research Institute, Wayne State University

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 10, 2007
Enrollment StartJun 1, 2007
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 18.9 years ago

Interventions

Valacyclovirdrug

1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic

Placebodrug

2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic